Although it is still unknown how increased adipose VEGFb levels or enhanced adipose perfusion would lead to alleviating or preventing metabolic syndrome in humans, Robciuc et al have proposed that it might be associated with an increased insulin delivery as a consequence of the expansion of the vascular density associated with the effect of VEGFb on the bioavailability of VEGF-A for VEGFR2 [21]. Here, VEGFA is linked to metabolic syndrome.